Precision BioSciences (DTIL) EV/EBIT: History & Chart

Precision BioSciences, Inc.(DTIL)

Biotechnology · Durham, NC

$6.28-0.03 (-0.48%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.

Durham, NC

67 employees

www.precisionbiosciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Amoroso

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Precision BioSciences, Inc. (DTIL)	$173.34M	N/A	N/A	N/A	N/A
Cue Biopharma, Inc. (CUE)vs ›	$177.29M	N/A	N/A	N/A	N/A
Coherus Oncology, Inc. (CHRS)vs ›	$169.95M	N/A	8.53x	141.14x	141.14x
Compass Therapeutics, Inc. (CMPX)vs ›	$171.61M	N/A	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$178.54M	N/A	N/A	N/A	N/A
Journey Medical Corporation (DERM)vs ›	$183.71M	N/A	50.33x	50.33x	50.33x
Inogen, Inc. (INGN)vs ›	$161.12M	N/A	189.93x	95.49x	94.46x
ALX Oncology Holdings Inc. (ALXO)vs ›	$158.25M	N/A	N/A	N/A	N/A
AN2 Therapeutics, Inc. (ANTX)vs ›	$194.49M	N/A	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$193.74M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Precision BioSciences, Inc. (DTIL)

$173.34M

N/A

Cue Biopharma, Inc. (CUE)vs ›

$177.29M

N/A

Coherus Oncology, Inc. (CHRS)vs ›

$169.95M